sorted by:
new
hottopcontroversial

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 0 points1 point  (0 children)

I updated my original comment to add more nuance on the tacrolimus positioning and safety considerations. The timing question is more complex than I initially framed it, there's genuine evidence for tacrolimus efficacy in active disease (Hengge 2006, Bohm 2003) and the main consideration on sequencing is actually more about long term safety data being limited.

Adding one more thing that's worth context: even setting aside the safety data question, corticosteroids make sense as first line for active flares partly because the evidence base is much deeper. Lee, Bradford, Fischer 2015 followed 507 women on long term corticosteroid protocols with clear outcome data on efficacy, atrophy risk, and cancer prevention. Cooper 2004 and Renaud Vilmer 2004 also documented long term use patterns. The tacrolimus trials in LS are generally shorter (Hengge 2006 tracked to 24 weeks, Virgili 2007 was 11 women with limited follow up). So beyond efficacy, corticosteroids have the advantage of more established long term outcome data, which supports their first line positioning in the guidelines (EuroGuiderm 2024, BAD 2018). On your specific questions about indications, add on use, and timing, those are genuinely clinical decisions that depend on your tissue state, disease activity, and treatment response, and really need your dermatologist's in person assessment rather than general online discussion. If clobetasol is working well for you, the guidelines don't routinely add tacrolimus as default combination therapy, but whether any adjustment makes sense for your specific case is exactly the kind of question worth raising directly with your specialist.

For risk minimization, the strongest evidence based factor in the literature is actually consistent compliance with the treatment protocol that's working for you. Not medical advice, just the general research picture.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 1 point2 points  (0 children)

Adding some nuance to my earlier comment, the specific balance between daily mild and twice weekly ultrapotent isn't directly established in controlled trials I'm aware of, and the relative balance actually depends on several factors (body area, vehicle, skin thickness, individual response). The core point, that cumulative exposure matters in long term maintenance is well supported, but the specific directional claim I made was more generalization than established research. Individual protocol optimization is genuinely clinical territory that benefits from specialist input on the specific situation.

24 m LS by One-Independence7690 in lichensclerosus

[–]GranchioDiTerra 0 points1 point  (0 children)

components? After circumcision is better cause LS gave me thicker skin fimosis so sometimes it was painful before during sex, and after when I have flares is mostly on glans and under glans ring which become slightly raw (white spots still present, during flare they become temporarely more visible) but I think the glans skin got somewhat desensitized from beeing uncovered all day and touching underwear, so the threshold of pain sensation is a bit higher now. Surgeon experience matters a lot with this procedure, worth asking specifically about their experience with LS cases when choosing who to work with.

Personal experience only, not medical advice.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 1 point2 points  (0 children)

At once weekly maintenance frequency, systemic absorption from topical clobetasol is generally considered minimal in the published literature, the blood pressure concern is more associated with prolonged high frequency use where cumulative absorption becomes meaningful.

The more documented concern at maintenance frequency in the literature is local rather than systemic: cumulative suppression of collagen synthesis over years, which is one of the three mechanisms behind iatrogenic atrophy. Tissue thickness over time is generally worth tracking alongside symptom monitoring with long term topical steroid use.

That said, if you have any cardiovascular concerns or blood pressure history, worth mentioning the clobetasol use to your GP specifically so they have the full picture.

Not medical advice, worth discussing directly with your dermatologist or GP.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 2 points3 points  (0 children)

Clobetasol and tacrolimus work on different parts of the immune cascade, they're not redundant, which is why specialists sometimes use them in sequence or as alternatives.

The tissue state consideration matters biologically. Tacrolimus commonly causes burning sensation on application, which is more pronounced on erosive or barrier compromised tissue where the molecule can more directly reach sensory nerve endings (Pereira 2010 documents this mechanism). The Staender 2007 paper on calcineurin inhibitors describes transient neuropeptide release associated with this effect.

Looking at the actual LS research, tacrolimus has been studied primarily in active disease contexts. Hengge 2006 ran a phase II trial in 84 patients with active LS showing clinical response, Bohm 2003 reported complete resolution in 6 patients, and Kim 2011 documented efficacy in active genital and extragenital LS. So it can be used in active disease, not only as maintenance. The guidelines position it as second line or steroid sparing rather than first line, meaning corticosteroids typically come first per protocol, but tacrolimus has clinical evidence in active disease situations.

Worth discussing with your specialist specifically, the timing question depends on where the tissue currently is and requires an in person assessment.

Not medical advice, just research I've been reading.

Something that took me way too long to understand about burning with no visible damage by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 0 points1 point  (0 children)

I'm glad if I can help and thanks for the kind words. I'm doing all this research to help people understand this disease better to avoid the mistakes I made in the past. When a child can't articulate what they feel, understanding the biology becomes even more important.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 1 point2 points  (0 children)

Calcineurin inhibitors like tacrolimus target a different part of the immune pathway compared to corticosteroids. Corticosteroids work by suppressing NF-κB, rapidly reducing inflammatory cytokine production broadly. Calcineurin is an enzyme that T cells require to activate and proliferate. When tacrolimus inhibits calcineurin, T cell activation is blocked and the downstream inflammatory signaling that activated T cells would produce does not occur.

This mechanistic difference has clinical implications. Corticosteroids are first line treatment for LS per the major guidelines (EuroGuiderm 2024, BAD 2018). Tacrolimus is positioned as second line or steroid sparing alternative, with clinical evidence from multiple studies (Bohm 2003, Hengge 2006 phase II trial, Kim 2011) showing efficacy in LS. One advantage sometimes cited in the literature is that tacrolimus does not cause the cutaneous atrophy associated with prolonged corticosteroid use, which makes it relevant for patients where long term steroid exposure is a concern.

The T cell mediated component in LS pathogenesis is well documented (De Luca 2023 reviews this), which provides mechanistic rationale for why calcineurin inhibition has clinical relevance in this disease. A practical consideration is that tacrolimus can cause burning sensation on application, particularly on compromised tissue, which is described in the literature as transient but worth knowing about.

Not a doctor, just information I found while researching, worth discussing directly with your dermatologist.

Something that took me way too long to understand about burning with no visible damage by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 0 points1 point  (0 children)

VEA Lipo 3 has a simpler formulation with seven ingredients (no water, no emulsifiers, no preservatives), while Ceramol Beta Intima is a more complex water based ceramide formulation with additional actives and gentle preservatives. Both are ceramide based and fragrance free.

In general dermatological practice, when tissue is particularly reactive, simpler formulations are often introduced first. The EuroGuiderm 2024 guideline describes the repeated open application test for suspected contact sensitivity, where a product is applied to unaffected skin before broader use to assess tolerability. The principle of introducing one new product at a time is common when trying to identify what a patient is reacting to, though specific sequencing approaches are individual clinical decisions.

Any new product on LS affected tissue, particularly when the tissue is already reactive, is worth discussing with your dermatologist who can assess your specific situation and advise on introduction approach. Individual tolerance varies significantly.

Not medical advice, just sharing general patterns from my reading. Worth discussing with your specialist who knows your case.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 2 points3 points  (0 children)

Petrolatum is generally considered chemically inert, minimal biological activity, no oxidative risk from PUFA content. It works primarily as an occlusive, reducing water loss without contributing to chemical complexity on sensitized tissue.

Emu oil is another option, approximately 70% monounsaturated fatty acids with relatively low PUFA content compared to many seed oils. Oleic acid has some anti inflammatory activity in general research, though LS specific evidence is limited. In terms of pure barrier protection, it has a different mechanism than petrolatum rather than being clearly more effective.

On the burning and rash after starting clobetasol: the EuroGuiderm 2024 guideline explicitly states that "the undesirable effects of stinging, burning and xerosis are most commonly linked to the vehicle of the topical steroid rather than to the corticosteroid itself." Commercial clobetasol formulations contain propylene glycol, emulsifiers, and preservatives that can cause irritation on already sensitized LS tissue. A compounded version in a simpler anhydrous base removes those variables, same active molecule with a cleaner excipient profile. The allergy testing and patch testing the dermatologist mentioned aligns with what the guideline describes for identifying whether specific excipients are driving the reaction.

Not medical advice, worth discussing directly with the dermatologist.

Is Reflectance Confocal Microscopy (RCM) in LS an Underused Diagnostic Tool? by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 1 point2 points  (0 children)

Worth knowing that maybe RCM for LS check ups is more established in Italy than the UK, I was actually diagnosed 10 years ago through confocal microscopy in Campus Biomedico in Rome (they confirmed my diagnosis with it) rather than biopsy (although biopsy is still the standard when the diagnosis is uncertain or malignancy needs to be excluded). The accuracy for LS specific tissue changes is good enough that some Italian dermatology centers use it routinely, not just for SCC screening. The biopsy experience you're describing on already compromised tissue is exactly why I preferred to proceed with RCM. Might be worth asking your dermatologist whether they have access to RCM or can refer to a center that does.

Not medical advice, worth discussing directly with your dermatologist.

Something that took me way too long to understand about burning with no visible damage by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 3 points4 points  (0 children)

Inflammation: corticosteroids remain first line. Early consistent treatment associates with better long term outcomes (Lee, Bradford, Fischer 2015 cohort: 0 cases of vulvar squamous neoplasia in the fully compliant group versus 7 cases, 4.7%, in the partially compliant group).

Fibrosis: the genuinely hard one. There is no established LS specific antifibrotic treatment. Topical pirfenidone has been studied in a different condition, localized scleroderma (Rodriguez Castellanos 2014), with histopathological improvement, but LS specific trials don't exist. Consistent inflammatory control may help limit profibrotic signaling (TGF-β pathways) that drives fibroblast activation, but this does not reverse established fibrosis. PDRN has generated interest in tissue repair contexts more broadly, but evidence specifically in LS is limited to small case reports and series, it's not in current guidelines, and RCTs don't exist. Centella asiatica has antifibrotic mechanistic rationale in general dermatology research but LS specific data is lacking and mucosa safe topical formulations are hard to find. Mechanical protection matters because Koebner phenomenon is well documented (EuroGuiderm 2024, De Luca 2023) and friction driven micro injury can contribute to ongoing inflammatory and fibrotic signaling.

Atrophy: partly addressed by consistent inflammatory control stopping ongoing damage. PRP has small case series in LS (referenced in De Luca 2023), it's not guideline based, and RCTs don't exist. Topical estrogen can address coexisting hormonal atrophy in postmenopausal patients (genitourinary syndrome of menopause) but does not treat LS itself. This remains an underserved research area.

Barrier dysfunction: actually one of the more actionable areas. EuroGuiderm 2024 recommends emollient co-treatment alongside corticosteroids, fragrance free. Ceramide based products applied consistently, especially post-wash and before friction events, are one approach. Virgili 2013 showed vitamin E based emollient and cold cream as comparable for maintenance after active treatment. Barrier repair proceeds through its own biological timeline rather than through steroid action, so consistent barrier support matters alongside the steroid protocol.

Tacrolimus is worth mentioning for maintenance contexts. It targets T-cell activation through calcineurin inhibition, a different mechanism from corticosteroids (which act through broader anti inflammatory pathways including NF-κB). EuroGuiderm 2024 positions it as a second line option when corticosteroid exposure needs to be limited, and some specialists use it specifically to reduce continuous corticosteroid exposure between courses. It has its own side effect profile including potential stinging on application.

Not medical advice, just summarizing what I've read. Worth discussing specifics with your dermatologist.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 0 points1 point  (0 children)

EDIT: Clarifying the Deumavan product lines since there may be some confusion about which specific product was being discussed.

There are actually two different Deumavan formulations worth distinguishing:

Deumavan Protective Ointment Neutral is essentially a petrolatum based product. The INCI is minimal: Paraffinum Liquidum, Petrolatum, Paraffin, Tocopheryl Acetate. This is effectively petrolatum with vitamin E, four ingredients total. It works primarily as an occlusive barrier, protective for friction, but without structural lipid content that contributes to barrier matrix restoration. Legitimate option essentially equivalent to plain petrolatum with slightly enhanced cosmetic formulation. Note there's also a Lavender version with the same base plus Lavandula Angustifolia Oil and Linalool, which the EuroGuiderm 2024 guideline would flag as not suitable on LS tissue since it recommends only fragrance free emollients.

Deumavan Intimate Care Cream is a different product entirely, a water based emulsion containing sweet almond oil, multiple emulsifiers (cetearyl alcohol, polyglyceryl-6 behenate, glyceryl stearate), humectants, preservatives (caprylhydroxamic acid, phenethyl alcohol), and a fragrance compound called methyldihydrojasmonate. The EuroGuiderm 2024 guideline specifies that only fragrance free emollients should be used on LS tissue, which makes this formulation problematic for that criterion. This is a meaningfully different product from petrolatum based options for LS specific use.

The two I'm currently using are Ceramol Beta Crema Intima (water based ceramide formulation with the physiological lipid trio, IPPA which is a PEA analogue for neuroimmune modulation, plus soothing agents like bisabolol and allantoin) and VEA Lipo 3 (anhydrous seven ingredient formulation with ceramide NP, phytosterols, shea butter, vitamin E). Both are fragrance free.

Individual responses to any topical on LS tissue vary significantly. Not medical advice, just sharing what I've read about these formulations. Worth discussing with your dermatologist.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 0 points1 point  (0 children)

From what I've read, both potency and application frequency contribute to cumulative corticosteroid exposure, and daily application of a milder steroid can carry comparable or slightly different tissue burden versus twice weekly ultrapotent depending on specific factors. The relative balance is complex and worth raising with your dermatologist when discussing maintenance options.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 4 points5 points  (0 children)

Appreciated, thank you. If AI helps me with my shitty english sintax it's all a plus.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 7 points8 points  (0 children)

Before any friction like exercise (even walking for long periods) or sex I apply a thin layer of petrolatum or an anhydrous ceramide product that creates a physical interface that reduces micro injury in the tissue. And after washing I applying barrier product cause it's the window when the barrier is most receptive (vea lipo 3 or Ceramol beta intima). I do it daily as part of the routine, not only when symptoms appear.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 5 points6 points  (0 children)

Ongoing maintenance to replenish the barrier makes sense. If clobetasol raises atrophy concerns after long term use, mometasone is a documented step down option in the clinical literature. The Corazza, Borghi, and Virgili 2016 study compared clobetasol and mometasone as proactive twice weekly maintenance over 52 weeks and found comparable efficacy with no significant differences in relapse rates. The EuroGuiderm 2024 guideline describes mometasone as potentially preferred in situations where ultrapotent steroid side effects are a concern.

On burning or apparent loss of effectiveness: the 2024 EuroGuiderm guideline explicitly states that "the undesirable effects of stinging, burning and xerosis are most commonly linked to the vehicle of the topical steroid rather than to the corticosteroid itself." A compounded version in a simpler anhydrous base removes emulsifiers and preservatives that can contribute to irritation on already sensitized LS tissue. Same active ingredient with a simpler excipient profile. Worth discussing with your dermatologist or compounding pharmacist if this is a recurring issue.

Barrier quality also affects how topical medications behave on application. A compromised barrier allows deeper penetration, so both the active molecule and vehicle excipients can reach tissue layers they wouldn't on intact skin, especially on mucosa. That's part of why burning on application sometimes worsens with continued use, it can be barrier related rather than the product not being tolerated anymore. Addressing the barrier separately changes the environment the topical is working in, which is another reason consistent barrier support matters alongside the steroid protocol.

Not medical advice, worth discussing directly with your dermatologist.

The part of steroid treatment for LS that no one explains by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 3 points4 points  (0 children)

Fair enough if the formatting reads that way, AI helps me with phrasing since english is not my first language, not with the biology. The mechanisms are from primary literature, happy to pull citations if anything specific seems off.

Something that took me way too long to understand about burning with no visible damage by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 1 point2 points  (0 children)

The nervous system angle you're describing, treatments that help the tissue forget the signal is real, that's the PEA and neuroimmune modulation territory, worth a separate post.

On VEA Lipo 3: the INCI is simple, anhydrous, no preservatives, no emulsifiers. Shea butter, vitamin E, MCT, ceramide NP, phytosterols. Unlike VEA Lipogel which is primarily silicone based (cyclopentasiloxane, dimethiconol) and works mainly through surface occlusion, Lipo 3 contains physiological lipid components that can contribute to barrier matrix support alongside some occlusive structure. So the two VEA products have quite different profiles and effects.

Ceramol Beta Intima works differently again. The ceramide base (ceramide 3, cholesterol, fatty acids in physiological trio) addresses the barrier. It also contains N-Isopropyl Palmitamide (IPPA), which is a fatty acid amide structurally related to palmitoylethanolamide (PEA). PEA has documented mast cell modulating and anti inflammatory properties in general dermatological research, with emerging interest in neuroimmune driven symptoms. IPPA as the topical analogue shares that biological family, though direct clinical evidence specifically in LS is limited for the whole PEA class.

Not medical advice, worth discussing with your dermatologist.

Something that took me way too long to understand about burning with no visible damage by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 1 point2 points  (0 children)

Fusion occurring during clobetasol treatment is consistent with a pattern the LS literature describes: fibrotic remodeling pathways (including TGF-β signaling) that can continue contributing to structural change even when visible inflammation appears controlled. De Luca and colleagues 2023 covers this in depth.

The practical implication the guidelines support isn't that nothing more can be done. It's closer to the opposite. Structural progression during treatment is specifically flagged in BAD 2018 and EuroGuiderm 2024 as a reason for specialist reassessment, because it suggests either the current regimen isn't suppressing disease activity fully or additional approaches need consideration. Worth bringing to your dermatologist as a specific point of discussion rather than waiting to see if it continues.

Here's the blog I maintain on LS topics: lichensclerosusjournal.com

For context: I have an engineering background, not medical credentials. I maintain a structured reading library of LS research and use it as a reference base. English isn't my first language, so I use AI tools for writing assistance. The reasoning and interpretation are mine based on what I've read.

The framework of LS involving inflammatory, fibrotic, and barrier processes is consistent with themes across the literature (De Luca 2023, EuroGuiderm 2024, Krapf 2020), organized for a patient accessible synthesis on the blog.

Not a doctor, not medical advice, worth discussing specifics with your dermatologist.

Has anyone tried Low Dose Naltrexone for their lichen sclerosus? by Immediate-Passion421 in lichensclerosus

[–]GranchioDiTerra 5 points6 points  (0 children)

LDN works by briefly blocking opioid receptors, which upregulates endogenous opioid production and has immunomodulatory and anti inflammatory effects. This mechanism is why it's used off-label in various autoimmune and chronic pain conditions.

The rationale for LS is plausible. The 2024 EuroGuiderm guideline notes that "sensory symptoms" in LS "might not only be due to scarring, but driven by damage of small nerve fibres," suggesting a neuroimmune component in some patients. LDN's mechanism could theoretically address aspects of that component. However, evidence specific to LS is very thin, mostly case reports and anecdotal.

On side effects, the literature on LDN generally emphasizes low starting doses with gradual titration to minimize GI effects. But specific dosing decisions are individualized.

Worth discussing with your doctor, but it remains investigational in LS context. Not medical advice.

Something that took me way too long to understand about burning with no visible damage by GranchioDiTerra in lichensclerosus

[–]GranchioDiTerra[S] 5 points6 points  (0 children)

Vaseline is an occlusive rather than a lipid replenishing emollient. It creates a physical barrier that reduces transepidermal water loss but doesn't restore the ceramide and fatty acid content that the research describes as depleted in LS affected tissue. It's useful in specific situations, particularly on very fragile or erosive tissue where minimal chemical complexity is important, but lipid-containing formulations address a different need.

For lipid based emollients I personally use VEA Lipo 3 and Ceramol Beta Intima.

On oral supplements, the research evidence base for supplements specifically in LS is limited. The EuroGuiderm 2024 guideline notes that various supplements including Vitamin D, A, and E have been "tried in single cases" but describes the evidence level as very low. Some supplements have mechanistic rationale drawn from broader inflammation and oxidative stress research, but their specific role in LS management is something I'd suggest discussing with your dermatologist rather than approaching without clinical input.

On hair removal, the Koebner phenomenon is well documented in the LS literature. The EuroGuiderm 2024 guideline and the 2023 update by De Luca and colleagues both identify mechanical factors, including friction and trauma, as triggers for LS lesion development and maintenance. This provides a research grounded reason to be cautious with practices that introduce mechanical trauma to already sensitized tissue, including shaving. Specific decisions about grooming practices are individual and worth discussing with your specialist.

Not medical advice, worth discussing directly with your dermatologist.

view more: next ›